Trailing Twelve Months Sales Growth: IGC Pharma, Inc. (IGC)

Strict government control over transportation guarantees the reliability of supply chains. The annual revenue growth rate (rolling period) on the GURU.Markets chart demonstrates stability, where -6.50 describes the current status of the metric. The financial potential of IGC Pharma, Inc. (IGC) is based on a closed patent portfolio for Alzheimer's disease therapy and the active expansion of its cannabinoid drug line to improve patient quality of life.
Summary analytical data breakdowns for IGC Pharma, Inc. (IGC)

IGC Pharma, Inc. (IGC) focuses on high-risk Alzheimer's disease research, where revenue depends on development stages. This indicator captures the daily price action of revenue changes over a rolling year relative to the previous period. The metric identifies the acceleration or deceleration of operating flows, signaling a shift in the fundamental trend. For a biotech company, this serves as a marker for the transition from laboratories to patent commercialization. By analyzing the year-over-year sales growth percentage for TTM, an investor determines the business scaling stage.